Autoimmune Oral Mucosal Diseases: Clinical, Etiologic, Diagnostic, and Treatment Considerations

Dental Clinics of North America

Volumn 55, Issue 1, 2011, Pages 89-103

  Sciubba, James J ^a  

^a GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Mucosal pemphigoid; Oral lichen planus; Oral mucosal diseases; Pemphigus vulgaris

Indexed keywords

AUTOIMMUNE DISEASE; HUMAN; LICHEN PLANUS; MOUTH DISEASE; MUCOUS MEMBRANE PEMPHIGOID; PATHOLOGY; PEMPHIGUS; REVIEW;

AUTOIMMUNE DISEASES; HUMANS; LICHEN PLANUS, ORAL; MOUTH DISEASES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGUS;

EID: 78649420758     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2010.08.008     Document Type: Review

References (33)

1. Ishii N., Maeyama Y., Karashima T., et al. A clinical study of patients with pemphigus vulgaris and pemphigus foliaceous: an 11-year retrospective study (1996-2006). Clin Exp Dermatol 2008, 33(5):641-643.
2. Kircheli D., David M., Frusic-Zlotkin M., et al. The distribution of pemphigus vulgaris Ig subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000, 143:337-342.
3. Mignogna M.D., Fortuna G., Leuci C. Oral pemphigus. Minerva Stomatol 2009, 58(10):501-518.
4. Ahmed A.R., Wagner R., Khatri K., et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A 1991, 88:5056-5060.
5. Harman K.E., Seed P.T., Gratian M.J., et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001, 144:775-780.
6. Endo H., Rees T.D., Hallmon W.W., et al. Disease progression from mucosal to mucocutaneous involvement in a patient with desquamative gingivitis associated with pemphigus vulgaris. J Periodontol 2008, 79(2):369-375.
7. Cirillo N., Prime S.S. Desmosomal interactome in keratinocytes: a systems biology approach leading to an understanding of the pathogenesis of skin diseases. Cell Mol Life Sci 2009, 66(21):3517-3533.
8. Nguyen B., Dusek R.L., Beaudry V.G., et al. Loss of desmosomal protein perp enhances the phenotypic effects of pemphigus vulgaris autoantibodies. J Invest Dermatol 2009, 129(7):1710-1718.
9. Femiano F. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Minerva Stomatol 2007, 56(4):215-223.
10. Calkins C.C., Setzer S.V., Jennings J.M., et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 2006, 281(11):7623-7634.
11. Delva E., Jennings J.M., Calkins C.C., et al. Pemphigus vulgaris IgG-induced desmoglein 3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism. J Biol Chem 2008, 283:18303-18313.
12. Scully C., Challacombe S.J. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations and management. Crit Rev Oral Biol Med 2002, 13(5):397-408.
13. Anhalt G.J., Kim S.C., Stanley J.R., et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990, 323:1729-1735.
14. Belloni-Fortina A., Faggion D., Pigozzi B., et al. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol Volume 2009, DOI:10.1155/2009/187864.
15. Huang C.H., Chen C.C., Wang C.J., et al. Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus. J Chin Med Assoc 2007, 70(2):65-70.
16. Markopoulos A.K., Antoniades D.Z., Zaraboukas T. Pemphigus vegetans of the oral cavity. Int J Dermatol 2006, 45(4):425-428.
17. Higgins G.T., Allan R.B., Hall R., et al. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa. Br J Ophthalmol 2006, 90(8):964-967.
18. Bhol K.C., Goss L., Kumari S., et al. Antibodies to human alpha 6 integrin in patients with oral pemphigoid. J Dent Res 2001, 80(8):1711-1715.
19. Bhol K.C., Colon J.E., Ahmed A.R. Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human β4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J Invest Dermatol 2003, 120(4):701-702.
20. Uitto J., Pulkkinen L. Molecular complexity of the cutaneous basement membrane zone. Mol Biol Rep 1996, 23(1):35-46.
21. Chan L. Human skin basement membrane in health and in autoimmune disease. Front Biosci 1997, 2:d343-d352.
22. Bedane C., McMillan J., Balding S., et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP 180 ectodomain: evidence that BP 180 spans the lamina lucida. J Invest Dermatol 1997, 108:901-907.
23. Fleming T.E., Korman N.J. Cicatricial pemphigoid. J Am Acad Dermatol 2000, 43:571-591.
24. Wozniak K., Kazama T., Kowlaewski C. A practical technique for differentiation of subepidermal bullous diseases. Arch Dermatol 2003, 139:1007-1011.
25. Bowers K.E., Sexton J., Sugerman P.B. Commentary. Clin Dermatol 2000, 18:497-498.
26. Sugerman P.B., Savage N.W., Walsh L.J., et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002, 13(4):350-365.
27. Scully C., Carrozzo M. Oral mucosal disease: lichen planus. Br J Oral Maxillofac Surg 2008, 46:15-21.
28. Carrozzo M., Brancatello F., Dametto E., et al. Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6?. J Oral Pathol Med 2005, 34:204-208.
29. Nakamura S., Hiroki A., Shinohara M., et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 82:556-563.
30. Shi P., Liu W., He Q.B., et al. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev 2010, 19:844-849.
31. Cianchini G., Corona R., Frezzolini A., et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007, 143(8):1033-1038.
32. Joly P., Roujeau J.C., D'Incan M., et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357(6):545-552.
33. Zambruno G., Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol 2008, 128(12):2745-2757.